Personalizing Immunotherapy in NSCLC Using PD-L1 and Tumor Mutation Burden as Biomarkers.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 34
- By:
- Publication type:
- Article
Works matching IS 21644403 AND DT 2019 AND VI 9 AND IP 5
Results: 15
1
2
Adding PARP Inhibitor to Immune Checkpoint Blockade Improves Responses in Ovarian Cancer with BRCA Mutations.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 32
- By:
- Publication type:
- Article
3
FDA Approves Keytruda plus Inlyta as First-Line Treatment for Advanced RCC.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 37
- Publication type:
- Article
4
Balversa Approved for Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 36
- Publication type:
- Article
5
Don't Blame Drug Prices on "Big Pharma" Lawmakers want lower list prices, but insurers are at fault for mismanaging plans.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 38
- By:
- Publication type:
- Article
6
First-Line Pembrolizumab plus Axitinib Combination Boosts Survival in Metastatic Renal-Cell Carcinoma.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 1
- By:
- Publication type:
- Article
7
Genomic Markers of Response Improve Patient Selection for Immune Checkpoint Inhibitor Therapy.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 29
- By:
- Publication type:
- Article
8
Sacituzumab, a Novel Antibody-Drug Conjugate, Shows Activity in Heavily Pretreated Urothelial Cancer.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 18
- By:
- Publication type:
- Article
9
Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 16
- By:
- Publication type:
- Article
10
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 1
- By:
- Publication type:
- Article
11
CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 26
- By:
- Publication type:
- Article
12
Darolutamide, New Androgen Receptor Inhibitor, Extends Metastasis-Free Survival in High-Risk Prostate Cancer.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 20
- By:
- Publication type:
- Article
13
Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 13
- By:
- Publication type:
- Article
14
Current Strategies in the Management of CINV.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 9
- By:
- Publication type:
- Article
15
Applying Business Principles to Everyday Practice.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 5, p. 1
- By:
- Publication type:
- Article